Anterior cervical discectomy and fusion (ACDF) is the most common treatment for degenerative disease of the cervical spine. Given the high rate of pseudarthrosis in multilevel stand-alone ACDF, there is a need to explore the utility of novel grafting materials. In this study, the authors present a single-institution retrospective study of patients with multilevel degenerative spine disease who underwent multilevel stand-alone ACDF surgery with or without cellular allograft supplementation.

In a prospectively collected database, 28 patients who underwent multilevel ACDF supplemented with cellular allograft (ViviGen) and 25 patients who underwent multilevel ACDF with decellularized allograft between 2014 and 2020 were identified. The primary outcome was radiographic fusion determined by a 1-year follow-up CT scan. Secondary outcomes included change in Neck Disability Index (NDI) scores and change in visual analog scale scores for neck and arm pain.

The study included 53 patients with a mean age of 53 ± 0.7 years who underwent multilevel stand-alone ACDF encompassing 2.6 ± 0.7 levels on average. Patient demographics were similar between the two cohorts. In the cellular allograft cohort, 2 patients experienced postoperative dysphagia that resolved by the 3-month follow-up. One patient developed cervical radiculopathy due to graft subsidence and required a posterior foraminotomy. At the 1-year CT, successful fusion was achieved in 92.9% (26/28) of patients who underwent ACDF supplemented with cellular allograft, compared with 84.0% (21/25) of patients who underwent ACDF without cellular allograft. The cellular allograft cohort experienced a significantly greater improvement in the mean postoperative NDI score (p < 0.05) compared with the other cohort.

Cellular allograft is a low-morbidity bone allograft option for ACDF. In this study, the authors determined favorable arthrodesis rates and functional outcomes in a complex patient cohort following multilevel stand-alone ACDF supplemented with cellular allograft.

颈椎前路椎间盘切除融合术（ACDF）是治疗颈椎退行性疾病最常见的方法。鉴于多级独立 ACDF 中假关节的高发生率，有必要探索新型移植材料的实用性。在这项研究中，作者提出了一项单一机构回顾性研究，研究对象是接受多节段独立 ACDF 手术的多节段退行性脊柱疾病患者，有或没有细胞同种异体移植补充剂。

在前瞻性收集的数据库中，确定了 28 名接受多水平 ACDF 辅以同种异体细胞移植 (ViviGen) 的患者和 25 名接受多水平 ACDF 并在 2014 年至 2020 年间进行脱细胞同种异体移植的患者。主要结果是由 1 年随访 CT 扫描确定的影像学融合。次要结果包括颈部残疾指数 (NDI) 评分的变化以及颈部和手臂疼痛的视觉模拟量表评分的变化。

该研究包括 53 名平均年龄为 53 ± 0.7 岁的患者，他们接受了多水平独立 ACDF，平均水平为 2.6 ± 0.7。两个队列之间的患者人口统计学相似。在同种异体细胞移植队列中，2 名患者出现术后吞咽困难，并在 3 个月的随访中得到解决。一名患者因移植物下沉而出现神经根颈椎病，需要进行后路椎间孔切开术。在 1 年 CT 中，92.9% (26/28) 接受 ACDF 补充细胞同种异体移植的患者成功融合，而接受 ACDF 而不接受同种异体细胞移植的患者为 84.0% (21/25)。与其他队列相比，同种异体细胞移植队列的平均术后 NDI 评分（p < 0.05）显着改善。

细胞同种异体移植是 ACDF 的低发病率同种异体骨移植选择。在这项研究中，作者确定了在多水平独立 ACDF 补充细胞同种异体移植后的复杂患者队列中有利的关节融合率和功能结果。